Search | Clinical Trials Finder

Conditions: Chronic Obstructive Pulmonary Disease, HIV, Emphysema
Interventions: blood draw, questionnaires, Lung function testing, Six-Minute walk test, Quantitative CT scans, Nasal secretion and cell collection, Echocardiogram; Procedure · Radiation
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Exercise Intervention, Medical Device Usage and Evaluation, Nutritional Intervention, Physical Performance Testing, Questionnaire Administration; Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Asthma, Wheezing, In Utero Nicotine, Pulmonary Function
Interventions: No current intervention; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 6 Months to 11 Years
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Indianapolis, Indiana • Portland, Oregon

Conditions: Amyotrophic Lateral Sclerosis, Dysphagia, Dyspnea, Respiration Disorders
Interventions: Experimental expiratory muscle strength training (EMST), Sham expiratory muscle strength training (EMST); Device
Lead sponsor: Cara Donohue; Other
Eligibility: 18 Years to 100 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Chest Pain, Shortness of Breath, Suspected Acute Coronary Syndrome
Interventions: Coronary CT Angiography, Stress Test; Procedure
Lead sponsor: St. Luke's-Roosevelt Hospital Center; Other
Eligibility: 45 Years and older
Enrollment: 411 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteogenesis Imperfecta
Interventions: Fresolimumab; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Portland, Oregon • Houston, Texas

Conditions: Heart Diseases, Lung Diseases
Interventions: Integrated CardioRespiratory System, Transthoracic Echocardiography (TTE), Electrocardiography; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Limb-girdle Muscular Dystrophy
Interventions: Not listed
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 11
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 8 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tetrahydrobiopterin (BH4), Antioxidant Cocktail; Drug · Dietary Supplement
Lead sponsor: Augusta University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Asthma
Interventions: Mepolizumab, Placebo, SOC; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more

Conditions: Asthma, Obesity
Interventions: Blood draw, Sputum collection, Pulmonary function test; Procedure
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Aerobic Exercise, Exercise Intervention, Educational Intervention, Dual X-ray Absorptiometry, Electronic Health Record Review, Cardiopulmonary Exercise Testing, Physical Performance Testing, Questionnaire Administration, Biospecimen Collection, Pulmonary Function Test; Other · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Asthma Acute, Asthma in Children, Asthma Chronic, Asthma Attack
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 6 Years to 15 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cystic Fibrosis in Children
Interventions: Infant PFT, Lung Clearance Index, Passive tidal breathing; Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: 1 Month to 5 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Abdominal Cancer, Pelvic Cancer
Interventions: Cardiopulmonary Exercise Testing (CPET); Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Muscular Dystrophy, Duchenne
Interventions: Cardiac MRI with contrast, Cardiac MRI without contrast, Blood Test, Heart Rate, Pulmonary Function Test, Genetic Testing, Repeat MRI scan; Other
Lead sponsor: Stanford University; Other
Eligibility: 7 Years to 21 Years · Male only
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: Los Angeles, California • Orange, California • Stanford, California

Conditions: Cystic Fibrosis
Interventions: Home lung function and symptom monitoring; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 14 Years and older
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Oropharyngeal Dysphagia
Interventions: 3-ounce water swallow test, Kayser-Jones Brief Oral Health Status Examination (BOHSE), Tongue pressure, Test of Masticating and Swallowing Solids (TOMASS), Respiratory function tests; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 60 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Complication of Transplanted Lung
Interventions: Aztreonam Lysine for Inhalation (AZLI), Status Post Lung Transplant; Drug · Procedure
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Los Angeles, California • Durham, North Carolina

Conditions: Asthma in Children
Interventions: Pilot study arm for technology-enhanced asthma intervention; Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 18 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Diaphragm Paralysis
Interventions: interscalene nerve block with 0.25% bupivacaine, interscalene block with 0.125% bupivacaine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cystic Fibrosis
Interventions: End tidal CO2 (EtCO2), Transcutaneous CO2 (TCO2), Capillary CO2 (CapCO2), Arterial blood gas (ABG); Other · Device · Diagnostic Test
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium, Olodaterol, Fluticasone propionate, Salmeterol; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 45
States / cities: Jasper, Alabama • Flagstaff, Arizona • Fullerton, California + 40 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Pulmonary Function Test, CT Scans, Questionnaires, MRI, Xenon gas; Diagnostic Test · Behavioral · Biological
Lead sponsor: Eric A. Hoffman; Other
Eligibility: 20 Years to 89 Years
Enrollment: 341 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2015
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes

Community-Based Exercise and Nutrition Training and Education Program for Cancer Survivors

Vitamin C Supplementation to Pregnant Smokers: Follow-up of 2 Randomized Trials Plus Changes in DNA Methylation

Fatigue in Patients With Amyotrophic Lateral Sclerosis

ProspEctive First Evaluation in Chest Pain Trial

Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta

Heart and Lung Function Monitoring System

A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice

Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

Pulmonary Inflammation and Microbiome Changes With Bariatric Surgery in Obese Asthma

Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial

User-Friendly Spirometer and Mobile App for Self-Management and Home Monitoring of Asthma Patients

Determinants of Early Cystic Fibrosis Lung Disease

A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMD

Early Intervention in Cystic Fibrosis Exacerbation

Oral and Swallowing Function in Older Adults

Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS)

Enhanced Community-Based Asthma Monitoring Through Novel Technology

The Effect of Interscalene Peripheral Nerve Block With 0.25% Bupivacaine vs 0.125% Bupivacaine on Lung Function

Comparative Analysis of CO2 Monitoring Methods in Patients With CF Undergoing General Anesthesia

The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus

Image and Model Based Analysis of Lung Disease